Create new artificial substances and useful processes

I have a lab‑scale formulation log and a list of candidate reagents with test results. Send the attached process-development summary to Dr. Singh in R&D and to finance for preliminary capex approval, with a Wednesday deadline — signers in that order. Confirm safety data sheets are attached and that any regulatory flags are noted before sending.

Before I send this to R&D and finance, make their review easy: pull the top-performing candidates into one table with yield, purity, and scale‑up risk column up front, show an estimated timeline and resource needs, and highlight any steps that need pilot permits so reviewers can approve or ask one focused question.

I ran three pilot runs and yields dropped by half when scaled. Dr. Singh will ask for root cause and finance will question further capex. I don’t know whether the loss is due to batch heating or reactant purity. What’s the likely diagnosis given the pattern, and what immediate tests or data should I provide so R&D and finance can decide whether to continue next Wednesday?

Across multiple projects we waste time because pilot reports list raw runs but never summarize expected cost per kilogram at scale or regulatory hold points. I lose funding and momentum. Which three reporting habits should I change — in summarizing yields, listing regulatory risks, and projecting capex — so scale‑up proposals get approved faster?